Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Fluorouracil 38Capecitabine 31Oxaliplatin 30Leucovorin 30Radiotherapy 21Irinotecan 20Bevacizumab 15Radiation 12Cetuximab 12pembrolizumab 9Gemcitabine 7trifluridine tipiracil drug combination 5dehydroftorafur 5cediranib 5Radiotherapy, Intensity-Modulated 5Folfox protocol 5Erlotinib Hydrochloride 5Cisplatin 5Carboplatin 5trametinib 4Surgical Procedures, Operative 4Paclitaxel 4Neoadjuvant Therapy 4Gene Expression Profiling 4Cyclophosphamide 4sargramostim 3binimetinib 3Trifluridine 3Sorafenib 3Pemetrexed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Rectal Neoplasms × bavituximab × Clear all
NCT01634685 2020-08-20

A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma

University of Texas Southwestern Medical Center

Phase 1 Completed
15 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡